XXXX therapy for problematic proliferating haemangioma.

@entity1 @entity154 @entity1169 @entity455 @entity851 @entity146 @entity134 @entity617 @entity2713
AIM: To evaluate the effectiveness and the safety of systemic and intralesional @entity134 therapy for problematic proliferating haemangioma. METHOD: 233 @entity1 with haemangioma were identified from our @entity455 database 1996-2007. 46 (36%) out of 129 @entity1 with proliferating haemangioma required intervention. 24 of these @entity1 received @entity134 therapy. Indications for @entity134 therapy, the response and side effects of treatment and the need for other treatment were recorded. Intralesional @entity2713 up to 4 mg/kg/injection was preferred for small, localised non-periorbital lesions in 5 @entity1 and oral @entity617 2.0-2.5 mg/kg/day was used for larger lesions, especially around the periorbital region in 19 @entity1 . RESULTS: Accelerated regression of the haemangioma was observed in four of the five @entity1 who received intralesional @entity2713 and there was no complication. Overall, the haemangioma in 17 (89%) of the 19 @entity1 responded to high dose oral @entity617 with accelerated regression noted in 10 (53%) @entity1 . Rebound growth was observed in 5 @entity1 during dose tapering, requiring dose increment in three @entity1 and debulking surgery in one @entity1 . Three @entity1 developed @entity851 during treatment but this normalised 3-10 months following cessation of @entity134 therapy. Other side effects included mild @entity154 (n=2), @entity146 (n=2), increased appetite (n=3). CONCLUSION: Intralesional and systemic @entity134 are relatively safe and effective in treating problematic proliferating haemangioma. Systemic @entity134 therapy is associated with few short-term side effects. A multidisciplinary management is essential. @entity1169 is likely to replace @entity134 as the first-line treatment for problematic proliferating haemangioma.
